Su YD - Search Results

1

A simple and accurate method to quantify real-time contraction of vascular smooth muscle cell in vitro.

Wang QW, Xu JY, Li HX, Su YD, Song JW, Song ZP, Song SS, Dong B, Wang SX, Li B. Wang QW, et al. Among authors: su yd. Vascul Pharmacol. 2023 Apr;149:107146. doi: 10.1016/j.vph.2023.107146. Epub 2023 Jan 29. Vascul Pharmacol. 2023. PMID: 36724828

2

Lysosome-Targeted Biosensor for the Super-Resolution Imaging of Lysosome-Mitochondrion Interaction.

Wang H, Fang G, Chen H, Hu M, Cui Y, Wang B, Su Y, Liu Y, Dong B, Shao X. Wang H, et al. Front Pharmacol. 2022 Mar 15;13:865173. doi: 10.3389/fphar.2022.865173. eCollection 2022. Front Pharmacol. 2022. PMID: 35370649 Free PMC article.

3

ATP6AP2 knockdown in cardiomyocyte deteriorates heart function via compromising autophagic flux and NLRP3 inflammasome activation.

Li L, Cui YJ, Liu Y, Li HX, Su YD, Li SN, Wang LL, Zhao YW, Wang SX, Yan F, Dong B. Li L, et al. Among authors: su yd. Cell Death Discov. 2022 Apr 4;8(1):161. doi: 10.1038/s41420-022-00967-w. Cell Death Discov. 2022. PMID: 35379787 Free PMC article.

4

Downregulation of the (pro)renin receptor alleviates ferroptosis-associated cardiac pathological changes via the NCOA 4-mediated ferritinophagy pathway in diabetic cardiomyopathy.

Zhang X, Dong X, Jie H, Li S, Li H, Su Y, Li L, Kang L, Dong B, Zhang Y. Zhang X, et al. Int Immunopharmacol. 2024 Sep 10;138:112605. doi: 10.1016/j.intimp.2024.112605. Epub 2024 Jul 3. Int Immunopharmacol. 2024. PMID: 38963979

5

Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.

Liang XL, Su YD, Li XB, Fu YB, Ma R, Yang R, Wu HL, Cui YR, Li Y. Liang XL, et al. Among authors: su yd. Ann Surg Oncol. 2024 Nov 13. doi: 10.1245/s10434-024-16485-1. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39538101

6

Effect of postoperative normothermic intraperitoneal chemotherapy on the prognosis of MPM patients receiving CRS+HIPEC: A single-center case-control study.

Liang XL, Su YD, Fu YB, Li XB, Ma R, Yang R, Wu HL, Li Y. Liang XL, et al. Among authors: su yd. Eur J Surg Oncol. 2024 Nov;50(11):108692. doi: 10.1016/j.ejso.2024.108692. Epub 2024 Sep 14. Eur J Surg Oncol. 2024. PMID: 39298871

7

Drug sensitivity tumor cell clusters in malignant peritoneal mesothelioma.

Su YD, Ma R, Fu YB, Wu HL, Liang XL, Liu YT, Yu Y, Yang ZR, Li Y. Su YD, et al. J Surg Oncol. 2024 Aug 25. doi: 10.1002/jso.27847. Online ahead of print. J Surg Oncol. 2024. PMID: 39183488

8

Development in the Study of Natural Killer Cells for Malignant Peritoneal Mesothelioma Treatment.

Liu YT, Wu HL, Su YD, Wang Y, Li Y. Liu YT, et al. Among authors: su yd. Cancer Biother Radiopharm. 2024 Oct;39(8):551-561. doi: 10.1089/cbr.2024.0078. Epub 2024 Aug 2. Cancer Biother Radiopharm. 2024. PMID: 39093850 Review.

9

Research progress of malignant peritoneal mesothelioma with paraneoplastic syndrome: A review.

Liang XL, Li XB, Fu YB, Su YD, Ma R, Yang R, Wu HL, Li Y. Liang XL, et al. Among authors: su yd. J Surg Oncol. 2024 Sep;130(3):533-542. doi: 10.1002/jso.27737. Epub 2024 Jul 31. J Surg Oncol. 2024. PMID: 39082465 Review.

10

Intraoperative urinary tract resection and construction in CRS + HIPEC procedures: a single center retrospective analysis.

Ji ZH, Fu YB, Liu G, Yu Y, Li B, Su YD, Yang R, Liang XL, Li Y. Ji ZH, et al. Among authors: su yd. World J Surg Oncol. 2024 Jun 26;22(1):171. doi: 10.1186/s12957-024-03457-8. World J Surg Oncol. 2024. PMID: 38926860 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

95 results

Search Page

Filters